Immune-based therapies for hepatocellular carcinoma
Top Cited Papers
Open Access
- 10 March 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Oncogene
- Vol. 39 (18), 3620-3637
- https://doi.org/10.1038/s41388-020-1249-9
Abstract
Hepatocellular carcinoma (HCC) is the third most frequent cause of cancer-related death. The immune-rich contexture of the HCC microenvironment makes this tumour an appealing target for immune-based therapies. Here, we discuss how the functional characteristics of the liver microenvironment can potentially be harnessed for the treatment of HCC. We will review the evidence supporting a therapeutic role for vaccines, cell-based therapies and immune-checkpoint inhibitors and discuss the potential for patient stratification in an attempt to overcome the series of failures that has characterised drug development in this disease area.Keywords
Funding Information
- Wellcome Trust (PS3416)
- Cancer Research UK (C57701/A26137)
- AstraZeneca (RSRO_P71752)
- Wellcome Trust Clinical Research Training Fellowship
This publication has 166 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- Increased Circulating Th17 Cells after Transarterial Chemoembolization Correlate with Improved Survival in Stage III Hepatocellular Carcinoma: A Prospective StudyPLOS ONE, 2013
- Promotion of Hepatocellular Carcinoma by the Intestinal Microbiota and TLR4Cancer Cell, 2012
- Organ-specific features of natural killer cellsNature Reviews Immunology, 2011
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunityThe Journal of Experimental Medicine, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- Oncogenic stress sensed by the immune system: role of natural killer cell receptorsNature Reviews Immunology, 2009
- A New Population of Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma Patients Induces CD4+CD25+Foxp3+ T CellsGastroenterology, 2008
- Sorafenib in Advanced Hepatocellular CarcinomaThe New England Journal of Medicine, 2008
- How regulatory T cells workNature Reviews Immunology, 2008